Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0YFOJD)
| ADC Name |
SGN-35C
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SGN-35C; PF-08046044
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Brentuximab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
|
Antigen Info | ||||
| Payload Name |
AMDCPT
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Unspecific non-hodgkin lymphoma | ||||
| Diffuse large B-cell lymphoma | ||||
| Mature T-cell lymphoma | ||||
| Hodgkin lymphoma |